Get the Stockscreener App
2.10
3.45%
0.07
After Hours:
2.10
Immunitybio Inc stock is traded at $2.10, with a volume of 9.97M.
It is up +3.45% in the last 24 hours and down -12.50% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.03
Open:
$2.03
24h Volume:
9.97M
Relative Volume:
1.05
Market Cap:
$2.00B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.1649
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-1.87%
1M Performance:
-12.50%
6M Performance:
-26.06%
1Y Performance:
-58.08%
1-Day Range:
$2.00
$2.15
1-Week Range:
$1.95
$2.15
52-Week Range:
$1.83
$5.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.10 | 2.00B | 1.31M | -597.65M | -425.62M | -0.97 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Can ImmunityBio Inc. (26CA) stock test all time highs2025 Top Decliners & Verified Stock Trade Ideas - newser.com
Is ImmunityBio Inc. (26CA) stock a safe buy pre earningsNew Guidance & Low Risk Entry Point Tips - newser.com
Why analysts upgrade ImmunityBio Inc. stock2025 Market Overview & Weekly High Return Opportunities - newser.com
Editor: 【Stock Selection Techniques】 - newser.com
What dividend safety rating applies to ImmunityBio Inc. (26CA) stock2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
Can ImmunityBio Inc. (26CA) stock sustain free cash flow2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Will ImmunityBio Inc. (26CA) stock extend growth story2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - newser.com
Will ImmunityBio Inc. (26CA) stock justify high valuation2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
How ImmunityBio Inc. (26CA) stock compares with tech leadersJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
ImmunityBio : Jefferies Global Healthcare Conference in London - MarketScreener
How ImmunityBio Inc. (26CA) stock responds to bond marketJuly 2025 Setups & Low Risk Profit Maximizing Plans - newser.com
Is ImmunityBio Inc. (26CA) stock a buy before earnings results2025 Retail Activity & Accurate Buy Signal Notifications - newser.com
Applying big data sentiment scoring on ImmunityBio Inc.Sell Signal & Smart Allocation Stock Tips - newser.com
Intraday pattern recognizer results for ImmunityBio Inc.Earnings Trend Report & Daily Profit Maximizing Tips - newser.com
Why retail investors favor ImmunityBio Inc. stockJuly 2025 Pullbacks & Free Growth Oriented Trading Recommendations - newser.com
What drives ImmunityBio Inc 26CA stock priceStock Split Announcements & Exceptional Return Stocks - earlytimes.in
Why ImmunityBio Inc. (26CA) stock is upgraded to buyJuly 2025 Rallies & Low Drawdown Investment Strategies - newser.com
ImmunityBio Inc. recovery potential after sell offJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Tick level data insight on ImmunityBio Inc. volatilityTrade Analysis Summary & Technical Confirmation Trade Alerts - newser.com
Will ImmunityBio's (IBRX) Surging Revenue and Lower Net Loss Shift Its Investment Narrative? - simplywall.st
Why ImmunityBio Inc. (26CA) stock is a strong analyst pickWeekly Trade Analysis & High Accuracy Investment Entry Signals - newser.com
Can machine learning forecast ImmunityBio Inc. recoveryJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Why ImmunityBio Inc. (26CA) stock stays undervaluedJuly 2025 Outlook & Daily Entry Point Alerts - newser.com
D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation - Nasdaq
ImmunityBio (IBRX): Assessing Valuation After Q3 Revenue Surge and Narrowed Losses - Yahoo Finance
How ImmunityBio's (IBRX) Revenue Surge and Narrowed Losses May Affect Investor Outlook - Yahoo Finance
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations - Business Wire
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):